Objective To report the response to progestin therapy in young women with endometrial complex atypical hyperplasia (CAH) or FIGO grade 1 endometrial adenocarcinoma (FIGO 1 EAC) based on clinicopathologic features, including abnormal DNA mismatch repair (MMR) by immunohistochemistry (IHC).
Introduction
Endometrioid endometrial adenocarcinomas are generally low-grade, responsive to oestrogen, and preceded by endometrial hyperplasia. 1, 2 While many of these cancers are curable with hysterectomy, fertility preservation may be a concern in 10-15% of patients who are premenopausal when diagnosed. Complex atypical hyperplasia (CAH), the precursor lesion of well-differentiated endometrial adenocarcinoma (FIGO 1 EAC), is diagnosed more commonly in postmenopausal women but poses similar management challenges in younger women. 3, 4 Many patients with CAH or FIGO 1 EAC have significant medical co-morbidities which place them at higher surgical risk and may make conservative management options more appealing. [5] [6] [7] Diagnosis of endometrial cancer and its precursor lesions in younger patients raises concern for Lynch syndrome, a hereditary cancer disorder in which germline mutations in DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) result in an increased lifetime risk of endometrial, ovarian, colorectal, and other cancers. Approximately 2-5% of endometrial cancers can be attributed to Lynch syndrome, and affected patients tend to present at a younger age. 8, 9 Defective DNA MMR is characteristic of Lynch-associated cancers. 10 The efficacy of oral progestin therapy in treating CAH and FIGO 1 EAC has been well-described. [11] [12] [13] [14] [15] [16] Although response rates vary, most studies report regression of CAH and FIGO 1 EAC in 75-90% and 70-75%, respectively, with use of oral progestins. Similar effects have been reported with the use of intrauterine progestin, the levonorgestrel intrauterine system (LNG-IUS). [17] [18] [19] Some studies report lower response rates and higher relapse rates in patients with FIGO 1 EAC (compared with CAH) and/or with higher body mass indices (BMI). 11, [13] [14] [15] 20 A randomised control trial comparing LNG-IUS and oral progestins has yet to be performed. 21, 22 The LNG-IUS may also be associated with less weight gain. 23 It is unclear whether patients with Lynch-associated endometrial cancer have worse clinical outcomes. [24] [25] [26] The role of somatic MMR gene mutations in determining prognosis also is not well described. [27] [28] [29] [30] [31] Studies evaluating endometrial adenocarcinomas in young women report a 16-34% incidence of abnormal immunochemistry (IHC) for DNA MMR proteins, and some describe its association with worse clinical outcomes. [29] [30] [31] Certain clinical factors have been associated with poor response to progestins, but whether defective MMR is associated with likelihood of response to progestin treatment remains unclear. 15, 20, 32, 33 Conservative management of CAH and FIGO 1 EAC may be of particular importance in patients with Lynch syndrome or Lynch-like tumours, as many of these patients desire fertility preservation. The objective of this study is to evaluate the response to progestin therapy in young women with CAH or FIGO 1 EAC based on MMR protein status.
Methods
After IRB approval, we performed a retrospective chart review of consecutive patients with histologically confirmed CAH or FIGO 1 EAC who were ≤55 years of age at diagnosis between 1 January 2000 and 31 December 2013. Only patients with presumed stage I disease based on exam and/or imaging studies and who underwent conservative management with progestin treatment (oral, intrauterine or injectable progestins, or any combination of these) for at least 3 months followed by repeat endometrial sampling or hysterectomy to allow for evaluation of response to treatment were included. A total of 84 patients from two separate institutions met our inclusion criteria.
Demographic and clinical data were abstracted from medical records. Type and duration of progestin treatment were documented for each patient. Response to treatment was ascertained from the pathology report associated with each endometrial specimen obtained. Follow-up interval was defined as time from diagnosis of CAH or FIGO 1 EAC to time of last documented visit within each institution. Disease regression was defined as resolution of CAH or FIGO 1 EAC and included diagnoses of complex hyperplasia without atypia, simple hyperplasia with or without atypia, or complete resolution of hyperplasia. Disease progression was defined as progression of CAH to FIGO 1 EAC, or of either CAH or FIGO 1 EAC to a higher grade endometrial cancer. Disease persistence was defined as an unchanged diagnosis of CAH or FIGO 1 EAC despite treatment. Recurrence was defined as the reappearance of a lesion that had initially regressed following progestin treatment.
Immunohistochemistry to assess expression of the protein products of Lynch syndrome MMR genes (MLH1, MSH2, MSH6, PMS2) was performed on sections of formalin-fixed paraffin-embedded endometrial specimens that had been submitted to the pathology laboratory at CedarsSinai Medical Center or Olive View-UCLA Medical Center for histopathologic diagnosis. IHC was performed in accordance with the manufacturers' recommendations using the reagents and protocols shown in Supporting Information Table S1 . Representative images of IHC staining for MMR proteins are shown in Supporting Information Figure 1 . Two gynaecologic pathologists who were blinded to patient outcome assessed and recorded the presence/absence of IHC staining for each of the four proteins in the presence of positive internal controls. Based on IHC results, each patient was charted as having normal (intact) or abnormal (loss of) MMR protein expression in CAH or FIGO 1 EAC; germline genetic testing was not required for inclusion in this study.
Statistical analysis was performed by the David Geffen School of Medicine Department of Medicine Statistic Core at the University of California, Los Angeles, using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Descriptive values of variables were expressed as frequencies with median and range for continuous variables. Differences between groups were compared using Chi-square or Fisher's exact tests for discrete variables. Univariable and multivariable logistic regression analyses were performed to assess the association of each clinicopathologic factor with disease response.
Results
The study cohort included 84 women ≤55 years of age who were diagnosed with CAH (n = 57; 68%) or FIGO 1 EAC (n = 27; 32%) within the stated time period. The median age at diagnosis was 36 years (range 24-55), and the median follow-up time, defined as time from initial diagnosis to date of last documented clinical visit, was 49 months (range 4-201). Mean BMI was 35 kg/m 2 (range 19-64). Six (7%) of the 84 patients had abnormal IHC staining for MMR proteins. Clinical and demographic characteristics of the entire cohort are presented in Table 1 .
All patients received progestin therapy as first-line treatment for at least three continuous months. The median duration of treatment was 12 months (range 3-90). In the majority of cases, progestin was discontinued due to disease regression or to disease progression with subsequent hysterectomy. In all, 43 (51%) patients received only oral progestins, 37 (44%) received oral and intrauterine progestins, three (4%) received oral and injectable progestins, and one (1%) received only intrauterine progestin therapy. Only four patients (5%) had a successful live birth after progestin treatment, all with assisted reproductive technologies.
Although 54 (64%) of the 84 patients demonstrated initial disease regression while on progestin therapy, 13 (24%) developed recurrence of CAH or FIGO 1 EAC. On final endometrial sampling or hysterectomy specimens, the endometrial lesion had regressed in 41 (49%) patients, had persisted in 27 (32%) patients, and had progressed in 16 (19%) patients. Of the 46 patients who ultimately underwent hysterectomy, five (11%) had negative pathology, two (4%) had hyperplasia without atypia, 12 (26%) had CAH, 20 (44%) had stage IA FIGO grade 1 EAC, five (11%) had stage I FIGO grade 2-3 EAC, one (2%) had stage IIIA FIGO grade 2 EAC, and one (2%) had stage IVB FIGO grade 2 EAC. A synchronous primary endometrioid ovarian cancer was found in one of the patients with stage IA FIGO grade 1 EAC. At last follow up, only the patient with stage IVB disease was dead of disease.
Of the 57 patients with an initial diagnosis of CAH, 35 (62%) demonstrated regression of CAH, 11 (19%) had persistent disease, and 11 (19%) progressed to EAC at the time of last endometrial sampling or hysterectomy. Of the 22 patients with persistence or progression of CAH, the median duration of treatment was 11.5 months. Of the 27 patients with FIGO 1 EAC, six (22%) had disease regression, 16 (59%) had persistent CAH or FIGO 1 EAC, and five (19%) had progression to a higher grade of endometrial cancer on their final endometrial specimens. Patients with an initial diagnosis of FIGO 1 EAC were significantly more likely than those with CAH to have disease persistence or progression while on progestin treatment (78 versus 39%; P = 0.001). Multivariable analysis confirms that initial lesion type (CAH versus FIGO 1 EAC) was a significant predictor of regression of disease (P = 0.003).
More patients with an initial diagnosis of FIGO 1 EAC ultimately underwent hysterectomy than those with CAH, 78 versus 44%, respectively (P = 0.005). Clinical characteristics compared by initial biopsy result are shown in Table 2 . Among the 60 patients ≤40 years of age at initial diagnosis, 34 (55%) demonstrated ultimate disease regression while on progestin therapy, versus seven of the 24 patients (29%) of those >40 years of age (P = 0.03). On multivariable analysis, younger age was a significant predictor of disease regression, with every 1-year increase in a woman's age decreasing the odds of disease regression by 11%, after adjusting for lesion type and BMI (P = 0.004). Regression rates, as well as ultimate resolution rates, were not statistically significantly different between those who had a BMI ≤30 kg/m 2 and those who had a BMI >30 kg/m 2 (36 versus 55%, respectively) (P = 0.1).
Of the six patients with abnormal MMR protein expression on IHC, five (83%) had FIGO 1 EAC on initial endometrial sampling, versus 22 (28%) of 78 with normal IHC staining (P = 0.01). Patients in the abnormal MMR staining group were older, 42 versus 36 years (P = 0.05), and had a lower BMI, 24 versus 36 kg/m 2 (P = 0.004). All patients in the abnormal staining group ultimately underwent hysterectomy. There was no difference in incidence of diabetes or hypertension between the groups. Following progestin treatment, final endometrial sampling or hysterectomy showed resolution of hyperplasia or malignancy in no patients in the abnormal staining group, versus 41 (53%) in the group with normal staining (P = 0.026). As no patients in the abnormal MMR staining group achieved histologic resolution, logistic regression could not be performed for this variable. Clinical characteristics compared using IHC staining for MMR proteins are shown in Table 3 .
On IHC staining, three patients had loss of both MSH2 and MSH6, two had loss of both MLH1 and PMS2, and one had loss of MSH6 alone. Lynch syndrome was confirmed by germline testing in three of the six patients with abnormal IHC staining for MMR proteins: two of these patients had germline MSH2 mutations and one had a germline MSH6 mutation. One of the three remaining patients had negative germline testing, and two have not been tested. None of the six patients in the abnormal MMR staining group met Amsterdam II criteria for germline mutation testing. 34, 35 Detailed characteristics of the six patients with abnormal IHC staining are shown in Table 4 .
Discussion

Main findings
In our cohort of young women with CAH or FIGO 1 EAC, 7% had abnormal IHC staining for MMR proteins in their initial endometrial specimens. Initial endometrial histology (FIGO 1 EAC versus CAH), older age, and abnormal MMR staining were all predictors of poor response to progestin therapy. Interestingly, none of the six patients with abnormal IHC staining for MMR proteins, including the three with confirmed germline Lynch syndrome mutations, met Amsterdam II family history criteria for germline mutation testing. Although the patient diagnosed at 33 years of age had an extensive family history of cancer, her first-degree relative had a diagnosis of pancreatic cancer, which is not considered a Lynch-associated cancer.
34,35
Strengths and limitations
Our study is multi-institutional and, to our knowledge, is the largest study to evaluate progestin response in young women with CAH or FIGO 1 EAC based on IHC staining for MMR proteins. IHC results were confirmed by two gynaecologic pathologists, and comprehensive patient follow-up information was available with a relatively long median follow-up interval of 49 months. Nevertheless, this study is limited by its retrospective nature and the small number of patients with abnormal IHC staining for MMR proteins. Additionally, the presence of MLH1 promoter hypermethylation was not assessed in the two patients with MLH1 and PMS2 protein loss. Hypermethylation could account for up to 25% of these endometrial cancer cases without an associated germline mutation. As MLH1 promoter hypermethylation has been reported in patients with germline MLH1 or PMS2 mutations, it is unclear whether these patients can truly be excluded from germline testing.
36-38
Interpretation
The incidence of abnormal IHC results in our study is lower than that reported by others, who cite a 16-34% incidence of abnormal IHC staining for MMR proteins in young women with endometrial cancer. [29] [30] [31] Our inclusion of CAH and only low-grade endometrial cancers could account for this difference. The initial regression rate in our cohort of 64% in response to progestin therapy is similar to that described in the literature, and the 24% recurrence rate of CAH or FIGO 1 EAC also falls within the wide range of relapse described in similar studies. [13] [14] [15] [16] 33 Contrary to the findings reported by others, BMI did not predict histologic response to treatment in our patient cohort, 15, 20, 33 but patients with abnormal MMR staining had lower BMI.
Conclusions
Our findings suggest that abnormal IHC staining for MMR proteins in young women with CAH or FIGO 1 EAC predicts poor response to progestin therapy. Moreover, our study demonstrates an at least 50% risk of germline mutation associated with abnormal IHC for MMR proteins in young patients with endometrial cancer, which further 
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